US › Healthcare

Celularity Inc (CELU)

US · Healthcare · Biotechnology

$1.27-1.55%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

$4.1M

Revenue YoY

-77.4%

Net profit

$-24.4M

EPS

$-1.02

Net margin

-593.6%

Key statistics

Market cap

$37.3M

Forward P/E

0.0

P/B

9.89

Book value

$-1.32

EPS (TTM)

$-3.73

52-week high

$2.55

52-week low

$0.56

50-day MA

$0.97

200-day MA

$1.13

Beta

0.80

Analyst view

Analysts rate Celularity Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $2.50.

Shareholding

Insiders

37.18%

Institutions

12.88%

Largest institutional holders

Fund	Stake
C V Starr & Co Inc	2.64%
Vanguard Capital Management, LLC	2.15%
Geode Capital Management, LLC	0.66%
BlackRock Inc	0.44%
Citadel Advisors Llc	0.34%
Vanguard Fiduciary Trust Co	0.28%
State Street Corp	0.20%
Northern Trust Corp	0.15%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Celularity Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.